This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klimas, N G
Right arrow Articles by Fletcher, M A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klimas, N G
Right arrow Articles by Fletcher, M A

 Previous Article  |  Next Article 

J Clin Microbiol. 1990 June; 28(6): 1403-1410

Immunologic abnormalities in chronic fatigue syndrome.

N G Klimas, F R Salvato, R Morgan and M A Fletcher

Miami Veterans Administration Medical Center, Florida.

ABSTRACT

The chronic fatigue syndrome (CFS), formerly known as chronic Epstein-Barr virus syndrome, is a clinical state of some complexity and uncertain etiology. In order to characterize in a comprehensive manner the status of laboratory markers associated with cellular immune function in patients with this syndrome, 30 patients with clinically defined CFS were studied. All of the subjects were found to have multiple abnormalities in these markers. The most consistent immunological abnormality detected among these patients, when compared with normal controls, was low natural killer (NK) cell cytotoxicity. The number of NK cells, as defined by reactivity with monoclonal antibody NKH.1 (CD56), was elevated, but the killing of K562 tumor cells per CD56 cell was significantly diminished. Lymphoproliferative responses after stimulation with phytohemagglutinin and pokeweed mitogen were decreased in most patients when compared with those in normal controls, as was the production of gamma interferon following mitogen stimulation. Lymphocyte phenotypic marker analysis of peripheral blood lymphocytes showed that there were significant differences between patients with CFS and controls. There was an increase in the percentage of suppressor-cytotoxic T lymphocytes, CD8, and a proportionally larger increase in the number of CD8 cells expressing the class II activation marker. Most patients had an elevated number of CD2 cells which expressed the activation marker CDw26. The numbers of CD4 cells and the helper subset of CD4+CD29+ cells in patients with CFS were not different from those in controls. There was, however, a significant decrease in the suppressor inducer subset of CD4+ CD45RA+ cells. The number of B cells, CD20 and CD21, were elevated, as were the numbers of a subset of B cells which coexpressed CD20 and CD5. The patterns of immune marker abnormalities observed was compatible with a chronic viral reactivation syndrome.

J Clin Microbiol. 1990 June; 28(6): 1403-1410




This article has been cited by other articles:

  • Puri, B K (2007). Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome). J. Clin. Pathol. 60: 122-124 [Abstract] [Full Text]  
  • Tellez, N., Comabella, M., Julia, E v., Rio, J., Tintore, M a., Brieva, L., Nos, C., Montalban, X. (2006). Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult Scler 12: 487-494 [Abstract]  
  • McDermott, C., Richards, S.C.M., Thomas, P.W., Montgomery, J., Lewith, G. (2006). A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. QJM 99: 461-468 [Abstract] [Full Text]  
  • Eisen, S. A., Kang, H. K., Murphy, F. M., Blanchard, M. S., Reda, D. J., Henderson, W. G., Toomey, R., Jackson, L. W., Alpern, R., Parks, B. J., Klimas, N., Hall, C., Pak, H. S., Hunter, J., Karlinsky, J., Battistone, M. J., Lyons, M. J., and the Gulf War Study Participating Investigators, (2005). Gulf War Veterans' Health: Medical Evaluation of a U.S. Cohort. ANN INTERN MED 142: 881-890 [Abstract] [Full Text]  
  • Jason, L. A., Holbert, C., Torres-Harding, S., Taylor, R. R. (2004). Stigma and the Term Chronic Fatigue Syndrome: Results of Surveys on Changing the Name. Journal of Disability Policy Studies 14: 222-228 [Abstract]  
  • Nijs, J., De Becker, P., De Meirleir, K., Demanet, C., Vincken, W., Schuermans, D., McGregor, N. (2003). Associations Between Bronchial Hyperresponsiveness and Immune Cell Parameters in Patients With Chronic Fatigue Syndrome. Chest 123: 998-1007 [Abstract] [Full Text]  
  • Afari, N., Buchwald, D. (2003). Chronic Fatigue Syndrome: A Review. Am. J. Psychiatry 160: 221-236 [Abstract] [Full Text]  
  • Demettre, E., Bastide, L., D'Haese, A., De Smet, K., De Meirleir, K., Tiev, K. P., Englebienne, P., Lebleu, B. (2002). Ribonuclease L Proteolysis in Peripheral Blood Mononuclear Cells of Chronic Fatigue Syndrome Patients. J. Biol. Chem. 277: 35746-35751 [Abstract] [Full Text]  
  • Natelson, B. H., Haghighi, M. H., Ponzio, N. M. (2002). Evidence for the Presence of Immune Dysfunction in Chronic Fatigue Syndrome. CVI 9: 747-752 [Full Text]  
  • Hanson, S. J., Gause, W., Natelson, B. (2001). Detection of Immunologically Significant Factors for Chronic Fatigue Syndrome Using Neural-Network Classifiers. CVI 8: 658-662 [Abstract] [Full Text]  
  • Wright, J B, Beverley, D W (1998). Chronic fatigue syndrome. Arch. Dis. Child. 79: 368-374 [Full Text]  
  • Bates, D. W., Buchwald, D., Lee, J., Kith, P., Doolittle, T., Rutherford, C., Churchill, W. H., Schur, P. H., Wener, M., Wybenga, D., Winkelman, J., Komaroff, A. L. (1995). Clinical Laboratory Test Findings in Patients With Chronic Fatigue Syndrome. Arch Intern Med 155: 97-103 [Abstract]  
  • Feder, H. M. Jr, Dworkin, P. H., Orkin, C. (1994). Outcome of 48 Pediatric Patients With Chronic Fatigue: A Clinical Experience. Arch Fam Med 3: 1049-1055 [Abstract]  
  • Vojdani, A., Brautbar, N., Campbell, A. (1994). Immunologic and Biologic Markers for Silicone. Toxicol Ind Health 10: 25-42  
  • Dooley, D. P. (1992). Commercial Laboratory Testing for Chronic Fatigue Syndrome. JAMA 268: 873-874 [Abstract]  
  • Buchwald, D., Cheney, P. R., Peterson, D. L., Henry, B., Wormsley, S. B., Geiger, A., Ablashi, D. V., Salahuddin, S. Z., Saxinger, C., Biddle, R., Kikinis, R., Jolesz, F. A., Folks, T., Balachandran, N., Peter, J. B., Gallo, R. C., Komaroff, A. L. (1992). A Chronic Illness Characterized by Fatigue, Neurologic and Immunologic Disorders, and Active Human Herpesvirus Type 6 Infection. ANN INTERN MED 116: 103-113 [Abstract]  
  • Fletcher, M. A., Klimas, N. (1991). Chronic Fatigue Syndrome. JAMA 265: 357-357 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»